NS-062, identified by its CAS number 2226257-92-5, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is characterized as a selective inhibitor of certain enzymes or receptors, which may play a role in various biological pathways. The compound's structure typically includes functional groups that enhance its binding affinity and specificity, making it a candidate for drug development. Its pharmacological profile suggests that it may exhibit effects on neurological or metabolic processes, although detailed studies are necessary to fully elucidate its mechanism of action and efficacy. Additionally, NS-062's solubility, stability, and bioavailability are critical factors that influence its potential as a therapeutic agent. As with many compounds in the research phase, ongoing investigations aim to determine its safety, toxicity, and overall therapeutic potential in clinical settings.

NS-062

2226257-92-5: NS-062, identified by its CAS number 2226257-92-5, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is characterized as a selective inhibitor of certain enzymes or receptors, which may play a role in various biological pathways. The compound's structure typically includes functional groups that enhance its binding affinity and specificity, making it a candidate for drug development. Its pharmacological profile suggests that it may exhibit effects on neurological or metabolic processes, although detailed studies are necessary to fully elucidate its mechanism of action and efficacy. Additionally, NS-062's solubility, stability, and bioavailability are critical factors that influence its potential as a therapeutic agent. As with many compounds in the research phase, ongoing investigations aim to determine its safety, toxicity, and overall therapeutic potential in clinical settings.

<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>

CAS 2226257-92-5

NS-062

NS-062

Ref: TM-T201773